Evidence map›Paper›PMID 39890423›Full record

ArticleJournal for immunotherapy of cancer2025

What's in a name? Memory NK cells for cancer immunotherapy.

Sean J Judge, Megan C Purl, William J Murphy, Robert J Canter

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Challenges and opportunities of human iPSC-derived NK as "Off-the-shelf" cellular therapies.Journal of experimental & clinical cancer research : CR · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sean J JudgeDivision of Surgical Oncology, Department of Surgery, University of California Davis School of Medicine, Sacramento, California, USA.
Megan C PurlDivision of Surgical Oncology, Department of Surgery, University of California Davis School of Medicine, Sacramento, California, USA.
William J MurphyDepartment of Dermatology, University of California Davis School of Medicine, Sacramento, California, USA.ORCID http://orcid.org/0000-0002-2793-401X
Robert J CanterDivision of Surgical Oncology, Department of Surgery, University of California Davis School of Medicine, Sacramento, California, USA rjcanter@ucdavis.edu.ORCID http://orcid.org/0000-0002-3331-5418

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The discovery that natural killer (NK) cells can retain features of "memory" from previous stimulation and pathogen exposure was a landmark advance highlighting one of many ways in which NK cells of the innate immune system resemble T cells of the adaptive immune system. This ability to "remember" prior stimulation to bring about enhanced protection of the host sparked significant excitement regarding potential therapeutic applications. Yet, how closely the features of naïve and memory NK cells recapitulate those of T cells remains unclear. Nonetheless, despite unresolved questions about the immunobiology of naïve and memory NK cells, the application of memory NK cells to the clinic for cancer and other indications has gathered steam to meet the unmet need for novel immunotherapies. Recent work from Arellano-Ballestero

Indexed as

Immunologic MemoryImmunotherapyKiller Cells, NaturalNeoplasmsAnimalsHumansAdaptiveAdoptive cell therapy - ACTImmunotherapyMemoryNatural killer - NK

Identifiers

PMID39890423
PMCPMC11792271

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.